Federal
Register Notices > Registrant
Actions - 2005 >
A-1 Distribution Wholesale; Denial of Registration
FR Doc 05-9833 [Federal Register: May 18, 2005 (Volume 70, Number 95)]
[Notices] [Page 28573-28574] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18my05-105]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
A-1 Distribution Wholesale; Denial of Registration
On October 8, 2004, the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration (DEA), issued an Order to Show Cause to
A-1 Distribution Wholesale (A-1) proposing to deny its September 19, 2002,
application for DEA Certificate of Registration as a distributor of list I
chemicals. The Order to Show Cause alleged that granting A-1's application would
be inconsistent with the public interest, as that term is used in 21
U.S.C. 823(h). The order also notified A-1 that should no request for a
hearing be filed within 30 days, its hearing right would be deemed waived.
According to the DEA investigative file, the Order to Show Cause was sent by
certified mail to A-1 at its proposed registered location at 6751 Macon Road,
Suite 18, Columbus, Georgia 31909. It was then forwarded by the U.S. Postal
Service to A-1's new address at 7565 Chattsworth Road, Midland, Georgia
31820-4026, where it was received on October 18, 2004. DEA has not received a
request for a hearing or any other reply from A-1 or anyone purporting to
represent the company in this matter.
Therefore, the Deputy Administrator of DEA, finding that (1) thirty days have
passed since delivery of the Order to Show Cause, and (2) no request for a
hearing having been received, concludes that A-1 has waived its hearing right.
See Aqui Enterprises, 67 FR 12,576 (2002). After considering relevant material
from the investigative file, the Deputy Administrator now enters her final order
without a hearing pursuant to 21
CFR 1309.53(c) and (d) and 1316.67.
The Deputy Administrator finds as follows.
List I chemicals are those that may be used in the manufacture of a
controlled substance in violation of the Controlled Substances Act. 21
U.S.C. 802(34); 21
CFR 1310.02(a). Pseudoephedrine and ephedrine are list I chemicals commonly
used to illegally manufacture methamphetamine, a Schedule II controlled
substance. As noted in previous DEA final orders, methamphetamine is an
extremely potent central nervous system stimulant, and its abuse is a persistent
and growing problem in the United States. See e.g., Direct Wholesale, 69 FR
11,654 (2004); Branex, Inc., 69 FR 8,682 (2004); Yemen Wholesale Tobacco and
Candy Supply, Inc., 67 FR 9,997 (2002); Denver Wholesale, 67 FR 99,986 (2002).
The Deputy Administrator's review of the investigative file reveals that on
or about September 19, 2002, an application was submitted by the owner of A-1,
Mr. David Smith, seeking registration to distribute ephedrine and
pseudoephedrine list I chemical products. The application originally included
phenylpropanolamine, but that listed chemical product was eventually deleted
from the request.
In connection with the pending application, an on-site pre- registration
investigation was conducted at the proposed premises in April 2003.
Investigators were advised that A-1 was a sole proprietorship, operated by Mr.
Smith and his wife, with no other employees. It commenced operations in June
2002 and was a wholesale distributor of general merchandise such as health and
beauty aids, automotive products, sunglasses and other sundry items. A-1
provided a list of products it intended to carry which included 60 tablet
bottles of Mini Two Way and Two Way brand combination ephedrine, as well as
Pseudo 60 brand pseudoephedrine. The majority of A-1's proposed customers were
gas stations, small retail markets and convenience stores in the Columbus,
Georgia area. Neither Mr. Smith nor his wife had any prior experience with the
distribution of list I chemicals.
DEA is aware that small illicit laboratories operate with listed chemical
products often procured, legally or illegally, from non- traditional retailers
of over-the-counter drug products, such as gas stations and small retail
markets. Some retailers acquire product from multiple distributors to mask their
acquisition of large amounts of listed chemicals. In addition, some individuals
utilize sham corporations or fraudulent records to establish a commercial
identity in order to acquire listed chemicals.
The Deputy Administrator has previously found that the illegal production of
methamphetamine continues unabated within the DEA Atlanta region. The adjacent
State of Tennessee leads the region in the number of clandestine laboratories
seized, accounting for approximately 50 percent of the clandestine laboratories
seized during the second quarter of 2002. When compared with the third quarter
of 2001, the increase in clandestine laboratory seizures is notable. According
to later records for the Atlanta region, 360 clandestine laboratories were
seized during the third quarter of 2002. Of the 360 laboratories seized during
that reporting period, 207 were located in Tennessee, 103 in Georgia, 35 in
South Carolina and 15 in North Carolina. See CWK Enterprises, Inc. (CWK), 69 FR
69,400 (2004); Prachi Enterprises, Inc. (Prachi), 69 FR 69,407 (2004).
In the State of Georgia, there has been a consistent increase in the number
of illicit laboratories and enforcement teams continue to note a trend toward
smaller capacity laboratories. This is likely due to the ease of concealment
associated with smaller laboratories, which continue to dominate seizures and
cleanup responses. The adjacent State of Tennessee also has a substantial
methamphetamine abuse problem in the Chattanooga and Eastern Tennessee areas and
DEA is aware of a past history of trafficking in precursors in these locations.
Distributors or retailers selling the illicit methamphetamine trade observe no
borders and trade across state lines. In fact, where precursor laws are
stringent, out-of-state distributors often make direct shipments to retainers
without observing state requirements. See CKW, supra, 69 FR 69,400; Prachi,
supra, 69 FR 69,407.
DEA knows by experience that there exists a "gray market'' in which certain
high strength, high quantity pseudoephedrine and ephedrine products are
distributed only to convenience stores and gas stations,
[[Page 28574]]
from where they have a high incidence of diversion. These grey market
products are not sold in large discount stores, retail pharmacies or grocery
stores, where sales of therapeutic over-the-counter drugs predominate. "Two-way''
ephedrine and single entity pseudoephedrine products are prime products in this
gray market industry and are rarely found in any retail store serving the
traditional therapeutic market.
DEA also knows from industry data, market studies and statistical analysis
that over 90% of over-the-counter drug remedies are sold in drug stores,
supermarket chains and "big box'' discount retailers. Less than one percent of
cough and cold remedies are sold in gas stations or convenience stores. Studies
have indicated that most convenience stores could not be expected to sell more
than $20.00 to $40.00 worth of products containing pseudoephedrine per month.
The expected sales of ephedrine products are known to be even smaller. Most
convenience stores handling gray market products often order more product than
what is required for the legitimate market and obtain chemical products from
multiple distributors.
Pursuant to 21 U.S.C.
823(h), the Deputy Administrator may deny an application for a Certificate
of Registration if she determines that granting the registration would be
inconsistent with the public interest. Section 823(h) requires that the
following factors be considered in determining the public interest:
(1) Maintenance of effective controls against diversion of listed chemicals
into other than legitimate channels;
(2) Compliance with applicable Federal, State and local law;
(3) Any prior conviction record under Federal or State laws relating to
controlled substances or to chemicals controlled under Federal or State law;
(4) Any past experience of the applicant in the manufacture and distribution
of chemicals; and
(5) Such other factors as are relevant to and consistent with the public
health and safety.
As with the public interest analysis for practitioners and pharmacies
pursuant to subsection (f) of section 823, these factors are to be considered in
the disjunctive; the Deputy Administrator may rely on any one of a combination
of factors and may give each factor the weight she deems appropriate in
determining whether a registration should be revoked or an application for
registration denied. See, e.g., Energy Outlet, 64 FR 14,269 (1999). See also,
Henry J. Schwartz, Jr., M.D., 54 FR 16,422 (1989).
The Deputy Administrator finds factors four and five relevant to the pending
application for registration.
With regard to factor four, the applicant's past experience in the
distribution of chemicals, the Deputy Administrator finds this factor relevant
based on Mr. and Mrs. Smith's lack of knowledge and experience regarding the
laws and regulations governing handling of list I chemical products. In prior
DEA decisions, this lack of experience in handling list I chemical products has
been a factor in denying pending applications for registration. See, e.g., CWK,
supra, 69 FR 69,400; Prachi, supra, 69 FR 69,407; Direct Wholesale, supra, 69 FR
11,654; ANM Wholesale, 69 FR 11,652 (2004); Xtreme Enterprises, Inc., 67 FR
76,195 (2002).
With regard to factor five, other factors relevant to and consistent with the
public safety, the Deputy Administrator finds this factor weighs heavily against
granting the application. Unlawful methamphetamine use is a growing public
health and safety concern throughout the United States and Southeast. Ephedrine
and pseudoephedrine are precursor products needed to manufacture methamphetamine
and operators of illicit methamphetamine laboratories regularly acquire the
precursor products needed to manufacture the drug from convenience stores and
gas stations which, in prior DEA decisions, have been identified as constituting
the grey market for list I chemical products. It is apparent that A-1 intends on
being a participant in this market.
While there are no specific prohibitions under the Controlled Substances Act
regarding the sale of listed chemical products to these entities, DEA has
nevertheless found these establishments serve as sources for the diversion of
large amounts of listed chemical products. See, e.g., ANM Wholesale, supra, 69
FR 11,652; Xtreme Enterprises, Inc., 67 FR 76,195; Sinbad Distributing, 67 FR
10,232 (2002); K.V.M. Enterprises, 67 FR 70,968 (2002).
The Deputy Administrator has previously found that many considerations
weighed heavily against registering a distributor of list I chemicals because, "[v]irtually
all of the Respondent's customers, consisting of gas station and convenience
stores, are considered part of the grey market, in which large amounts of listed
chemicals are diverted to the illicit manufacture of amphetamine and
methamphetamine.'' Xtreme Enterprises, Inc., supra, 67 FR at 76,197. As in
Xtreme Enterprises, Inc., lack of a criminal record and intent to comply with
the law and regulations are far outweighed by A-1's lack of experience and the
company's intent to sell ephedrine and pseudoephedrine primarily to the gray
market. See also, CWK, supra, 69 FR 69,400; Prachi, supra, 69 FR 69,407.
Based on the foregoing, the Deputy Administrator concludes that granting the
pending application would be inconsistent with the public interest.
Accordingly, the Deputy Administrator of the Drug Enforcement Administration,
pursuant to the authority vested in her by 21
U.S.C. 823 and 824
and 28 CFR 0.100(b) and 0.104, hereby orders the pending application for DEA
Certificate of Registration, previously submitted by A-1 Distribution Wholesale,
be, and it hereby is, denied. This order is effective June 17, 2005.
Dated: May 9, 2005.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05-9833 Filed 5-17-05; 8:45 am]
BILLING CODE 4410-09-M
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|